Literature DB >> 20100763

Longitudinal assessment of intellectual achievement in patients with classical galactosemia.

Peter Schadewaldt1, Björn Hoffmann, Hans-Werner Hammen, Gudrun Kamp, Susanne Schweitzer-Krantz, Udo Wendel.   

Abstract

OBJECTIVE: To conduct a longitudinal assessment of long-term cognitive outcome in patients with classical galactosemia.
METHODS: Inclusion criteria were (1) previous assessment of IQ dating back >10 years with tests being comparable with the recent German tests HAWIK-III and HAWIE-R, (2) absence of illnesses other than galactosemia, (3) absence of foreign language problems, (4) enzymatic-metabolic proof of classical galactosemia, (5) compliance with dietary therapy, and (6) written informed consent. Twenty-three patients who fulfilled these criteria were found. They underwent the first IQ test at a mean age of 11 +/- 5 years and the second 13.6 to 15.5 years later at a mean age of 26 +/- 5 years. Results were corrected for the obsolescence of test norms (Flynn effect).
RESULTS: Mean total IQ scores on the first and second tests were 78 +/- 14 and 73 +/- 15, respectively, and not significantly different. IQ scores in the average range were observed for 7 patients on the first test and for 5 patients on the second test. For 17 patients, the intraindividual IQ scores remained essentially unchanged. Five patients showed a decrease and 1 an increase of the IQ score over time. No consistent pattern of change was found with respect to performance or verbal IQ subscores or in achievements in the individual subtest.
CONCLUSIONS: The results confirm the presence of reduced cognitive ability in classical galactosemia and present evidence for an absence of substantial galactosemia-induced aggravation of this impairment with increasing age, at least in patients from 4 to 40 years of age. It remains to be clarified whether a reduction of cognitive function in galactosemia may be initiated by an in utero toxicity of endogenously formed galactose and which role such a process may play in the development of intellectual deficiencies that are later maintained throughout life.

Entities:  

Mesh:

Year:  2010        PMID: 20100763     DOI: 10.1542/peds.2008-3325

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  13 in total

1.  Introduction to the Maastricht workshop: lessons from the past and new directions in galactosemia.

Authors:  Gerard T Berry; Louis J Elsas
Journal:  J Inherit Metab Dis       Date:  2010-11-30       Impact factor: 4.982

2.  Living situation, occupation and health-related quality of life in adult patients with classic galactosemia.

Authors:  Björn Hoffmann; Nico Dragano; Susanne Schweitzer-Krantz
Journal:  J Inherit Metab Dis       Date:  2012-03-24       Impact factor: 4.982

3.  Cross-sectional analysis of speech and cognitive performance in 32 patients with classic galactosemia.

Authors:  Björn Hoffmann; Udo Wendel; Susanne Schweitzer-Krantz
Journal:  J Inherit Metab Dis       Date:  2011-02-24       Impact factor: 4.982

4.  Diversity of approaches to classic galactosemia around the world: a comparison of diagnosis, intervention, and outcomes.

Authors:  Patricia P Jumbo-Lucioni; Kathryn Garber; John Kiel; Ivo Baric; Gerard T Berry; Annet Bosch; Alberto Burlina; Ana Chiesa; Maria Luz Couce Pico; Sylvia C Estrada; Howard Henderson; Nancy Leslie; Nicola Longo; Andrew A M Morris; Carlett Ramirez-Farias; Susanne Schweitzer-Krantz; Susanne Scheweitzer-Krantz; Catherine Lynn T Silao; Marcela Vela-Amieva; Susan Waisbren; Judith L Fridovich-Keil
Journal:  J Inherit Metab Dis       Date:  2012-03-27       Impact factor: 4.982

5.  The adult galactosemic phenotype.

Authors:  Susan E Waisbren; Nancy L Potter; Catherine M Gordon; Robert C Green; Patricia Greenstein; Cynthia S Gubbels; Estela Rubio-Gozalbo; Donald Schomer; Corrine Welt; Vera Anastasoaie; Kali D'Anna; Jennifer Gentile; Chao-Yu Guo; Leah Hecht; Roberta Jackson; Bernadette M Jansma; Yijun Li; Va Lip; David T Miller; Michael Murray; Leslie Power; Nicolle Quinn; Frances Rohr; Yiping Shen; Amy Skinder-Meredith; Inge Timmers; Rachel Tunick; Ann Wessel; Bai-Lin Wu; Harvey Levy; Louis Elsas; Gerard T Berry
Journal:  J Inherit Metab Dis       Date:  2011-07-21       Impact factor: 4.982

6.  Systematic Review and Meta-analysis of Intelligence Quotient in Early-Treated Individuals with Classical Galactosemia.

Authors:  Lindsey Welling; Susan E Waisbren; Kevin M Antshel; Hugh-Owen Colhoun; Matthias Gautschi; Stephanie Grünewald; Rebecca Holman; Johanna H van der Lee; Eileen P Treacy; Annet M Bosch
Journal:  JIMD Rep       Date:  2017-04-09

7.  Cryptic residual GALT activity is a potential modifier of scholastic outcome in school age children with classic galactosemia.

Authors:  Emily L Ryan; Mary Ellen Lynch; Elles Taddeo; Tyler J Gleason; Michael P Epstein; Judith L Fridovich-Keil
Journal:  J Inherit Metab Dis       Date:  2013-01-15       Impact factor: 4.982

8.  The prevalence and clinical study of galactosemia disease in a pilot screening program of neonates, southern iran.

Authors:  S Senemar; Ah Ganjekarimi; S Senemar; B Tarami; M Bazrgar
Journal:  Iran J Public Health       Date:  2011-12-31       Impact factor: 1.429

9.  From mind to mouth: event related potentials of sentence production in classic galactosemia.

Authors:  Inge Timmers; Bernadette M Jansma; M Estela Rubio-Gozalbo
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.240

Review 10.  Fertility preservation in female classic galactosemia patients.

Authors:  Britt van Erven; Cynthia S Gubbels; Ron J van Golde; Gerard A Dunselman; Josien G Derhaag; Guido de Wert; Joep P Geraedts; Annet M Bosch; Eileen P Treacy; Corrine K Welt; Gerard T Berry; M Estela Rubio-Gozalbo
Journal:  Orphanet J Rare Dis       Date:  2013-07-16       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.